

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am an original, first and joint inventor of the subject matter, which is claimed and for which a utility patent is sought on the invention entitled:

the specification of which:

- ☐ was filed on \_\_\_\_\_, as United States non-provisional application  
U.S.S.N. \_\_\_\_\_, bearing Attorney Docket No. \_\_\_\_\_.
- ☒ is attached hereto.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56.

- ☐ I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT International application designating at least one country other than the United States listed below and have also identified below any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

[illegible]

☐ I hereby claim the benefit under Title 35, United States Code, § 119(e) or §120 of any United States application(s), or §365(c) of any PCT International application(s) designating the United States of America listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

<b>Application No.</b> <i>(U.S.S.N.)</i>	<b>Filing Date</b> <i>(dd/mm/yy)</i>	<b>Status</b> <i>(Patented, Pending, Abandoned)</i>

PCT International Applications designating the United States:

<b>PCT International Application No.</b>	<b>PCT Filing Date</b>	<b>Status</b>

I hereby appoint the following attorneys and/or agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

<b>Attorney or Agent</b>	<b>Registration No.</b>	<b>Attorney or Agent</b>	<b>Registration No.</b>
Kevin Ainsworth	39,586	Shane Hunter	41,858
Ingrid Beattie	42,306	David E. Johnson	41,874
William Belanger	40,509	Christina Karnakis	45,899
Charles E. Bell	48,128	Kristin E. Konzak	44,848
Naomi Biswas	38,384	Cynthia Kozakiewicz	42,764
Bradford C. Blaise	47,429	Barry J. Marenberg	40,715
Sean M. Coughlin	48,593	A. Jason Mirabito	28,161
David F. Crosby	36,400	Michel Morency	Limited Recognition
Christopher J. Cuneo	42,450	Carol H. Peters	45,010
Brian C. Dauphin	40,983	David Poirier	43,007
Brett N. Dorny	35,860	Michael Renaud	44,299
Marianne Downing	42,870	Brian Rosenbloom	41,276
Ivor R. Elrifi	39,529	Robert J. Sayre	42,124
Heidi A. Erlacher	45,409	C. Eric Schulman	43,350
John M. Garvey	37,833	Gregory J. Sieczkiewicz	48,223
James G. Gatto	32,694	Thomas M. Sullivan	39,392
Richard Gervase	46,725	Janine Susan	46,119
Matthew J. Golden	35,161	Nicholas P. Triano III	36,397
Sonia K. Guterman	44,729	Howard Susser	33,556
John A. Harre	37,345	Raphael A. Valencia	43,216
Brian P. Hopkins	42,669		

all of MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO PC, One Financial Center, Boston, Massachusetts 02111, as Applicant's attorneys with full power of substitution and revocation to take any and all action necessary with regard to the above-identified patent.

Address all telephone calls to Barry J. Marenberg, Esq., at telephone number 617/348-3099.

Address all correspondence to:

Ivor R. Elrifi, Ph.D., Esq.  
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.  
One Financial Center  
Boston, Massachusetts 02111

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or patent issued thereon.

\_\_\_\_\_  
Inventor's Signature

\_\_\_\_\_  
Date

Full Name of Inventor: Gregory H. Altman

Citizenship: United States of America

Residence: United States of America

Post Office Address: 377 High Street, Medford, Massachusetts 02115

\_\_\_\_\_  
Inventor's Signature

\_\_\_\_\_  
Date

Full Name of Inventor: David L. Kaplan

Citizenship: United States of America

Residence: United States of America

Post Office Address: 42 Pond Street, Concord, Massachusetts 01742

Inventor's Signature \_\_\_\_\_

Date \_\_\_\_\_

Full Name of Inventor: Rebecca L. Horan

Citizenship: United States of America

Residence: United States of America

Post Office Address: 100 Loomis Ridge, Westfield, Massachusetts 01085

TRA 1595953v1

Figure 1 consists of 12 sub-graphs labeled (a) through (l), each showing the growth of *E. coli* O157:H7 over a 24-hour period. The y-axis represents the concentration in log<sub>10</sub> CFU/g, ranging from 0 to 10. The x-axis represents time in hours, ranging from 0 to 24. The graphs show different growth curves for various strains and conditions, including control, heat treatment, and various chemical treatments.

- (a) Control: Shows a typical growth curve starting at 10<sup>2</sup> CFU/g and reaching 10<sup>8</sup> CFU/g by 24 hours.
- (b) Heat treatment: Shows a growth curve starting at 10<sup>2</sup> CFU/g and reaching 10<sup>8</sup> CFU/g by 24 hours.
- (c) Control: Shows a typical growth curve starting at 10<sup>2</sup> CFU/g and reaching 10<sup>8</sup> CFU/g by 24 hours.
- (d) Heat treatment: Shows a growth curve starting at 10<sup>2</sup> CFU/g and reaching 10<sup>8</sup> CFU/g by 24 hours.
- (e) Control: Shows a typical growth curve starting at 10<sup>2</sup> CFU/g and reaching 10<sup>8</sup> CFU/g by 24 hours.
- (f) Heat treatment: Shows a growth curve starting at 10<sup>2</sup> CFU/g and reaching 10<sup>8</sup> CFU/g by 24 hours.
- (g) Control: Shows a typical growth curve starting at 10<sup>2</sup> CFU/g and reaching 10<sup>8</sup> CFU/g by 24 hours.
- (h) Heat treatment: Shows a growth curve starting at 10<sup>2</sup> CFU/g and reaching 10<sup>8</sup> CFU/g by 24 hours.
- (i) Control: Shows a typical growth curve starting at 10<sup>2</sup> CFU/g and reaching 10<sup>8</sup> CFU/g by 24 hours.
- (j) Heat treatment: Shows a growth curve starting at 10<sup>2</sup> CFU/g and reaching 10<sup>8</sup> CFU/g by 24 hours.
- (k) Control: Shows a typical growth curve starting at 10<sup>2</sup> CFU/g and reaching 10<sup>8</sup> CFU/g by 24 hours.
- (l) Heat treatment: Shows a growth curve starting at 10<sup>2</sup> CFU/g and reaching 10<sup>8</sup> CFU/g by 24 hours.